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Abstract
AIM: To investigate the predictability of interleukin-28B single nucleotide 
polymorphism rs12979860 with respect to sustained virological response 
(SVR) in chronically  hepatitis  C virus  (HCV) genotype-1 patients treated 
with  a  protease-inhibitor  and  pegylated  interferon- (Peg-INF-)  based 
triple-therapy. 
METHODS:  We  searched  PubMed,  the  Cochrane  Library  and  Web  of 
Knowledge for studies regarding the interleukin 28B (IL-28B)-genotype and 
protease-inhibitor  based  triple-therapy.  Ten studies  with  2707  patients 
were  included  into  this  meta-analysis.  We  used  regression  methods  in 
order to investigate determinants of SVR. 
RESULTS: IL-28B-CC-genotype patients achieved higher SVR rates (odds 
5.34, CI: 3.81-7.49) than IL-28B-non-CC-genotype patients (1.88, CI: 1.43-
2.48)  receiving  triple-therapy.  The  line  of  therapy  (treatment-naïve  or 
-experienced for Peg-INF-) did not affect the predictive value of IL-28B (P 
= 0.1). IL-28B-CC-genotype patients treated with protease inhibitor-based 
triple-therapy consisting of Boceprevir, Simeprevir, Telaprevir or Vaniprevir 
2showed odds of 1.86, 9.77, 4.51 and 0.89, respectively.  The  odds for CC 
genotype patients treated with Faldaprevir cannot be quantified, as only a 
single study with a 100% SVR rate was available.
CONCLUSION:  IL-28B-SNP  predicts  the  outcome  for  chronic  HCV 
genotype-1 patients receiving protease inhibitor-based triple-therapy. The 
predictive value varies between the different protease inhibitors.
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Core tip: Hepatitis C is a world health problem and represents a dynamic 
field  of  research  for  new  therapeutic  options.  Recently  direct  antiviral 
agents such as protease inhibitors have been developed which, in addition 
to pegylated interferon- and Ribavirin, obtain higher sustained virological 
response (SVR) rates. Of note, costs are higher and side effects are more 
common. The data regarding the predictive value of Interleukin 28B  (IL-
28B) are controversial. This meta-analysis was conducted on 2707 patients 
treated  with  different  protease  inhibitors.  Its  aim  was  to  clarify  the 
predictive  value  of  IL-28B  on  SVR  in  protease  inhibitor-based  triple-
therapy, allowing the possibility of personalized treatment.
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3INTRODUCTION
Hepatitis C virus (HCV) is a global health Problem. According to the World 
Health  Organization,  approximately  150  million  people  are  chronically 
infected with HCV, and it is estimated that more than 350 thousand are 
dying each year[1].  HCV is  responsible in Europe and North America for 
50% of liver cirrhosis and 25% of hepatocellular carcinoma[2-4].
HCV  has  7  genotypes  (1  to  7)  and  approximately  100  subtypes [5]. 
Genotype  1,  which  is  the  most  common  HCV  genotype  in  Western 
countries, has the worst prognosis and response to antiviral treatment in 
comparison to other genotypes[6-8].
In the last years the standard therapy (Standard of care, SOC) for HCV 
consisted  of  pegylated  Interferon- (Peg-IFN-)  and  Ribavirin  (RBV)[9]. 
Recently, several direct antiviral agents (DAA) were developed, such as 
the protease inhibitors (PI) Boceprevir (BOC), Telaprevir (TVR), Vaniprevir 
(VNP),  Faldaprevir  (FLP)  and  Simeprevir  (SMP)[10-13].  In  pivotal  studies, 
patients treated with BOC or TVR and Peg-IFN-/RBV achieved significantly 
higher sustained virological response (SVR) rates compared to standard 
therapy[11-14]. These new treatment options bring new hopes for chronically 
HCV infected patients but they have more side effects and higher costs[10]. 
Treatment predictors are important tools for the management of therapy 
in patients with chronic HCV infection. For the current standard treatment 
with Peg-IFN-/RBV in patients with chronic HCV infection, HCV genotypes 
2 and 3, low baseline viral load, ethnicity, younger age, low  -GT levels, 
low -GT/ALT level, absence of advanced fibrosis/cirrhosis, and absence of 
steatosis in the liver have been identified as independent pretreatment 
predictors of a SVR[15,16].
After  initiation  of  treatment,  rapid  virological  response  (RVR, 
undetectable HCV-RNA at week 4 of therapy) is the best predictor of SVR 
independent  of  HCV  genotype[16].  Recently,  several  genome-wide 
association studies showed that a single nucleotide polymorphism (SNP) 
within the interleukin 28B (IL-28B)  gene is  significantly  associated with 
treatment  outcome  under  standard  treatment  in  chronically  HCV 
genotype-1  infected  patients[17-19].  IL-28B  rs12979860  is  the  most 
4investigated allele of IL-28B in Europe and North America. The data about 
the  predictive  value  of  IL-28B-genotype  in  HCV  genotype-1  and  triple-
therapy are inconsistent. In the studies with VNP, IL-28B-genotype had no 
predictive value for the treatment[13,20]. In the studies by Poordad et al[21], 
Fried et al[22], Bronowicki  et al[23], Sulkowski  et al[24] and Akuta et al[25], IL-
28B-CC-genotype had a favorable prognosis. In the study by Flamm et al[26] 
for  Boceprevir,  genotype  IL-28B-TT  had  a  favorable  prognosis  and  by 
Jacobson et al[27] and Pol  et al[28], IL-28B-genotype had a limited influence 
on  SVR.  However,  more  information  about  the  predictability  of  IL-28B-
genotype would allow physicians to individualize antiviral HCV therapy.
Therefore, we conducted this meta-analysis to investigate the predictive 
value of IL-28B rs12979860 (CC vs CT + TT) allele for SVR in chronically 
HCV genotype-1 infected patients treated with a triple-therapy regimen 
consisting of a DAA (BOC, TVR VNP, FLP or SMP) and Peg-IFN-/RBV.
MATERIALS AND METHODS
We searched  in  PubMed,  Web of  Knowledge  and  the  Cochrane  Library 
databases,  for  relevant  articles  (full  text  and meeting  abstracts)  up to 
January 2014 regarding the following the next  key words:  “Boceprevir” 
or/and  “SCH503034”,  “Telaprevir”  or/and  ”VX-950”,  “Ciluprevir”  or/and 
“BILN  2061”,  “Simeprevir”  or/and  ”TMC435”,  “Danoprevir”  or/and 
“R7227”,  “Vaniprevir”  (“MK-7009”),  “MK-5172”,  “Faldaprevir” 
(“BI201335”),  “Narlaprevir”  (“SCH900518”),  “Asunaprevir”  (“BMS-
650032”), “PHX1766”, “GS-9256”, “GS-9451”, “ABT450”, “IDX320”, “ACH-
1625”. All these DAAs were used as search words in order to avoid missing 
studies which have determined IL-28B polymorphism for a triple therapy. 
Because a large number of patient samples were retrospectively tested for 
IL-28B  genotype  and  some  of  these  results  were  only  presented  in 
meetings, we have decided to include also the meeting abstracts in our 
meta-analysis. In order to identify relevant studies, the references of the 
articles  included  were  manually  searched.  We  did  not  find  any  other 
articles that corresponded to our inclusion criteria. The studies search was 
performed using manual search for Cochrane Library and EndNote X7 for 
PubMed and Web of Knowledge databases.
5The inclusion criteria were: studies with human subjects, more than 18 
years of age, HCV genotype-1 patients, treatment with triple-therapy (IFN 
therapy-naïve  and  –experienced)  with  determined  IL-28B  genetic 
polymorphism  for  rs12979860  allele.  Only  articles  in  English  were 
included. The exclusion criteria were: HCV/HIV or HCV/HBV co-infection, 
liver  transplantation  recipients,  pediatric  studies  and  IL-28B  genetic 
polymorphism other than rs12979860. SVR was defined as undetectable 
HCV-RNA 24 wk after end of treatment. 
The studies were reviewed independently by two authors (NCM and AA). 
All differences were resolved by consensus among these two authors. Our 
analysis  was based on the original  published data.  For  consistency we 
refrained from contacting the authors of the individual studies. From the 
studies,  the  following  data  were  extracted:  First  author,  year  of 
publication,  type  of  patients  (IFN  therapy-naïve  or  -experienced),  total 
number  of  patients,  the  number  of  patients  with  determined  IL-28B-
genotype, type of DAA, IL-28B genetic polymorphism.
The statistical analysis was performed by CR. We used logistic regression 
to model the chance of a SVR and investigate potential influential factors. 
In a logistic regression, binary outcome data are modeled based on the 
odds of  events  (here:  SVR).  As  is  usual  regression,  the  odds are  then 
formulated  as  a  function  of  (potential)  explanatory  variables.  Random 
effects  were  included in  order  to  accommodate  heterogeneity  between 
studies[29].  As  the  available  data  allow  to  fit  a  multitude  of  plausible 
variations  of  regression models  to the data,  we approached the  model 
selection problem via Bayesian Information Criterion (BIC)[30], which allows 
to compare and select models based on a single adequacy measure. All 




Four  thousand  three  hundred  and  thirty-seven  studies  were  initially 
identified on the bases of DAAs. After removing duplicate citations, the 
remaining  1522  studies  were  searched  for  data  regarding  IL-28B 
6polymorphism  and  qualified  for  abstract  review.  Among  the  remaining 
studies, 1454 studies had no data regarding IL-28B and were excluded. 
The rest 68 studies were selected for a “full paper review“. Among these 
remaining 68 studies, five of them were reviews. Four of them included 
only interferon-free therapy. There were three meta-analyses which were 
excluded. Five studies described only SOC therapy. Another 41 studies and 
meeting abstracts, including preliminary and subgroup analysis from large 
trials  data,  rs8099917 IL-28B allele  and non-human studies,  had  to  be 
excluded (Figure 1).
This  meta-analysis  is  based  on  the  following  10  studies:  7  full  text 
studies and 3 meeting abstracts with a total of 2707 IL-28B patients. The 
studies of Akuta  et al[25], Bronowicki  et al[23], Jacobson  et al[27] and Pol  et 
al[28] investigated  the  interaction  between IL-28B  genotype  and  SVR  in 
patients receiving TVR based triple-therapy. The study from Akuta et al[25] 
had no patients with IL-28B genotype receiving SOC. The studies of Flamm 
et al[26] and Poordad  et al[21] analyzed the BOC based triple-therapy. VNP 
was used as DAA in the studies of Lawitz  et al[20] and Manns et al[13]. For 
SMP and FLP only one study could be included for each of them (Fried et 
al[22] and Sulkowski et al[24]; Table 1). 
Comparison of dual and triple therapy
Figure 2 illustrates the estimated odds and associated confidence intervals 
of  a  SVR,  contrasting  dual  and  triple  therapy,  and  CC  and  non-CC 
genotypes. When using conventional dual therapy, the  odds for SVR are 
around 0.34 for non-CC genotype (corresponding to  P 25% probability), 
which increases to 1.98 (P = 66%) for CC genotype. For triple therapy the 
odds are more favorable, 1.88 (P=65%) for non-CC and 5.34 (P = 84%) for 
CC genotype. The interaction effect between genotype and type of therapy 
is significant (P = 0.00126), i.e., the odds ratio between genotypes differs 
between therapy types (and vice versa). According to the BIC, this model, 
including a treatment indicator (double  vs triple), a genotype effect and 
their interaction fits the data best models that we investigated. In addition 
including subsets of the above variables or use a treatment indicator are 
also differentiating between different types of DAA.
7Comparison of individual DAA types
In addition to the results that came out as best-fitting according to the BIC, 
we  also  analyzed  the  analogous  results  where  protease  inhibitor-based 
triple-therapy is broken down into individual subtypes (DAAs). Comparing 
this model and the previous one (including interactions in both cases) in 
an  ANOVA,  the  difference  between  DAAs  actually  is  significant  (P = 
0.0013).  The  resulting  estimates  are  illustrated  in  Figure 3.  Among the 
different DAA types, the estimated odds for SVR tend to be larger than for 
double therapy and greater for CC than for non-CC genotype. The only two 
exceptions were VNP, where SVRs for both genotypes appeared to be of 
the same order of magnitude and FLP, where the CC-odds could not be 
quantified. For FLP, our data originate from a single study with a 100% SVR 
rate (22 out of 22 patients) for CC genotype; so all we can say is that the 
evidence  is  supports  effectiveness  of  FLP  in  CC  genotype  patients. 
Otherwise, for the CC genotype, the greatest odds for SVR are estimated 
for  SMP  (OR  14.71,  corresponding  to  P = 94%),  whilst  for  non-CC 
genotypes, the greatest odds are estimated for VNP (OR 3.28, P=77%). As 
in the previous model, the interaction effect between treatment type and 
genotype was significant (P < 0.001).
Effect  of  patient  type  (IFN--treatment-naïve  vs  IFN--
experienced)
Consideration  of  the  patient  type  (IFN--treatment-naïve  patients  vs 
patients having previously experienced IFN- treatment) in the regression 
model did not improve the model fit. Even in the best-fitting model among 
the  ones  including  a  patient-type  effect,  the  patient  type  regarding 
previously IFN- therapy was not significant (P = 0.1).
DISCUSSION
The main results of this meta-analysis are: I) IL28B-CC-genotype patients 
receiving protease inhibitor-based triple-therapy have a higher SVR rate 
than the IL-28B-non-CC-genotype patients with the same treatment type, 
8II)  considering sub-types of  DAAs,  the effect  appears to be present for 
BOC, FLP, SMP and TLP, but possibly not for VNP; III) IL-28B-CC-genotype 
patients have higher SVR rates both, in IFN-naïve and IFN experienced.
Genome-wide  association  studies  in  2009  showed  that  different 
polymorphisms in the region of IL-28B are associated with SVR in patients 
chronically  infected  with  HCV  genotype-1,  treated  with  Peg-INF- and 
RBV[17-19]. The IL-28B gene is located on the 19 chromosome. The molecular 
and immunological  mechanism of  the IL-28B influence on SVR remains 
unclear[17-19].  Lately  a  dinucleotide  polymorphism  ss469415590  (TT/G) 
was described to be a better genetic predictor, as IL-28B (INF-3) for HCV 
clearance  in  chronically  HCV genotype-1  infected  patients  treated  with 
SOC[31-33].  Moreover, only the G of this dinucleotide polymorphism creates 
a novel type III interferon protein, IFN-4. Absence of IFN-4 protein is thus 
supposed to favor resolution of HCV infection[31,33]. 
The determination of IL-28B rs12979860 genotype can help to shorten 
the therapy duration. Genotyping of IL-28B polymorphisms can further be 
used to improve patient compliance, to remain on treatment in spite of 
side  effects  and  to  defer  treatment  in  patients  with  low  likelihood  of 
response[34].  The  American  Association  for  the  Study  of  Liver  Diseases 
suggests IL-28B polymorphism as a robust predictive marker for treatment 
decision with Peg-INF-/RBV or in combination with DAA. Testing is useful if 
it  impacts the treatment decision of either patient or physician. Also in 
studies  with  interferon-free  therapy  regimens  IL-28B-CC-polymorphism 
was associated with better early viral kinetics and higher reduction of viral 
RNA[35]. Other interferon-free treatment regimens replicated these findings 
for IL-28B genotypes[36]. 
Recently,  a  pangenotypic  polymerase inhibitor  named sofosbuvir  was 
approved in the United States of America and Europe for the treatment of 
chronically HCV-infected patients. In selected patients sofosbuvir achieves 
an  SVR  rate  of  approximately  90%.  However,  a  24-wk  therapy  with 
sofosbuvir  and  ribavirin  costs  about  US$  169000[37].  Cost-effectiveness 
analysis show that there is no need to treat patients with IL-28B-CC allelic 
variation with sofosbuvir urgently because they do not necessarily benefit 
9from such a therapy referring to the SVR rate[38]. Nevertheless, regarding 
the economic aspects the second-generation protease inhibitors will not be 
cheaper.  For  this  reason,  we  need  more  information  about  predictive 
factors  in  order  to  detect  the  individuals  who  benefit  most  from  an 
antiviral  treatment  with  polymerase  inhibitors.  Through  the  use  of 
predictive factors it will be possible to achieve the highest rate for SVR and 
the least side effects as well as reducing the cost significantly. Certainly, 
the IL-28B polymorphisms will play a major role in the future. 
Our analyzes showed that IL-28B-CC patients could be treated with a 
protease inhibitors, either with FLP or SMP. Patients with IL-28B-CC who 
were treated with either FLP or SMP showed a SVR rate of 100% or 94%, 
respectively. Therefore, patients with IL-28B-CC genotype could be treated 
preferably with either FLP or SMP and the IL-28B-non-CC genotypes could 
be treated preferably with either the polymerase inhibitor sofosbuvir or 
with a combination of polymerase and protease inhibitors in case of an 
interferon-intolerance[37].
The difference between the IL-28B SNP predictive effect in triple and 
dual therapy is significant, suggesting that the effect of IL-28B on the odds 
of a SVR is smaller for triple-therapy than for dual-therapy.
Regarding BOC, the individual studies initially had contradictory results. 
The  study  conducted  by  Flamm  et  al[26] showed  that  for  the  IL-28B-TT 
rs12979860 genotype BOC had a favorable prognosis. However this study 
had a smaller number of participants than the SPRINT2 and RESPOND2 
trials. Poordad, et al[21] analyzed the data from these studies and showed 
that IL-28B-CC rs12979860 genotype patients were more likely to achieve 
a SVR. Our analysis showed that in the case of the patients treated with 
BOC the CC-genotype has a favorable prognosis.
For FLP and SMP, we could only include one study each, with a relatively 
small number of participants. For FLP, the odds for the CC genotype could 
not be quantified, due to the fact that our data originate from a single 
study with 100% SVR rate, indicating a strong beneficial effect.
In the case of SMP, the IL-28B-CC-genotype has the second best  odds 
among all  DAAs, but with a large  CI because of  the limited number of 
patients that were included in  the study.  Therefore,  future studies  with 
1these  DAAs  are  needed  to  confirm  these  results.  Our  meta-analysis 
showed that SMP based triple therapy is more likely to produce SVR in CC-
genotype  patients;  therefore  we  recommend  IL-28B  genotyping  before 
initiation of this treatment.
The studies  by Pol  et  al[28] and Jacobson  et al[27] showed that  IL-28B-
genotype  has  a  limited  and  non-significant  predictive  value  for  a  SVR 
regarding the triple-therapy with TVR. Both of them are analyses of the 
data from larger trials (Pol et al[28] from REALIZE and Jacobson et al[27] from 
ADVANCE US) stipulating that TVR based triple-therapy increase the SVR 
rate  through  all  IL-28B  genotypes,  especially  for  the  IL-28B-non-CC 
genotype patients. In our analysis TVR based regimes included a larger 
number of studies (n = 4). The results were significantly favorable for IL-
28B-CC-genotype patients. This result can be explained by the fact that 
Akuta et al[25] studied the predictive value of IL-28B-genotype only in Asian 
patients infected with genotype 1B, with higher SVR rates while the other 
studies included wider ranges of ethnicities.
IL-28B SNP has a predictive role for both, IFN-naïve and IFN-previously 
treated patients. For the SOC-double therapy this meta-analysis did not 
show evidence for a difference in treatment effect between patient types.
The strong points of our meta-analysis is the large number of patients (n 
= 2707), the included studies were randomized, controlled studies and the 
inclusion of various number of DAA types (n = 5). The limitations of our 
meta-analysis are the relatively small number of studies for some DAAs 
types (SMP, FLP), even though both, full text and meeting abstracts were 
included  into  the  search.  Another  limitation  to  our  study could  be  the 
absence of information on the influence of baseline viral loads on SVR and 
race in correlation with the IL-28B SNP. No long-term data are available 
yet. Furthermore, this meta-analysis reflects the methodological problems 
of the included studies.
In conclusion, the IL-28B allelic variation has a predictive value in the 
protease  inhibitor-based  triple-therapy  of  chronically  HCV  genotype-1 
infected patients and it differs among DAA types. However, the effect on 
the odds of a SVR is smaller than the one regarding IL-28B and SOC. We 
recommend  IL-28B  genotyping  also  in  the  case  of  SMP-based  triple 
1therapy.  VNP based regime was  the  only  triple  therapy which  was  not 
associated  with  higher  SVR  rates  for  IL-28B-CC-genotype  patients. 
Furthermore,  prospective  studies  need  to  be  conducted  for  the 
understanding of IL-28B-genotype predictive role in HCV triple-therapy. 
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Background
Hepatitis C is a world health problem and represents a dynamic field of 
research for new therapeutic options. The interleukin-28B  (IL-28B) single 
nucleotide  polymorphism  (SNP)  is  a  predictor  of  sustained  virological 
response  for  hepatitis  C  genotype-1  patients  treated  with  pegylated-
Interferon- and ribavirin as the standard of care. Recently, direct antiviral 
agents have been developed which, in addition to the standard of care, 
obtain higher sustained virological response rates, but with higher costs 
and side effects.
Research frontiers
IL-28B is a solid genetic predictor in the therapy of hepatitis C patients 
treated with interferon and ribavirin. In the era of new therapeutic options 
for hepatitis C, the current research hotspot is to evaluate the predictive 
value of IL-28B in different protease inhibitor-based triple-therapies. 
Innovations and breakthroughs
This  meta-analysis  demonstrates  that  IL-28B has  a  predictive  value  on 
protease  inhibitor-based  triple-therapy.  This  predictability  differs  among 
protease inhibitors.
Applications
This  study suggests  that  IL-28B could  be  used  as  a  genetic  predictive 
factor for antiviral response in hepatitis C genotype 1 patients treated with 
protease inhibitor-based triple-therapy.
1Terminology
Direct  antiviral  agents such as protease inhibitors  are newly developed 
drugs  against  hepatitis  C.  In  combination  with  Interferon  and  Ribavirin 
they  constitute  the  triple  therapy  for  hepatitis  C.   SNP  within  the 
interleukin  28B gene as  a  genetic  marker  is  associated with  sustained 
virological response in the treatment of hepatitis C.
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Figure 1: Flow chart  of  systematic  review of  protease inhibitor  based 
triple therapy. 
1Figure 2: Odds/probabilities of obtaining a sustained virological response 
with regard to interleukin 28B-genotype and different  therapy regimen. 
The  differences  between  the  shown  estimates  correspond  to  the  odds 
ratios.  A  greater  difference  of  odds  between the  both  IL-28B-genotype 
corresponds  to  a  more  beneficial  effect. SVR:  Sustained  virological 
response; IL-28B: Interleukin 28B.
2Figure  3: Odds/probabilities  of  a  sustained  virological  response with 
regard to interleukin 28B-genotype in different protease inhibitor based 
triple therapy. The differences between the shown estimates correspond to 
the odds ratios.  A greater difference of  odds between the both IL-28B-
genotype  corresponds  to  a  more  beneficial  effect. SVR:  Sustained 
virological response; IL-28B: Interleukin 28B.
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